Active, not recruitingPhase 2NCT02843035
Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension
Studying Gaucher disease type 1
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Genzyme, a Sanofi Company
- Principal Investigator
- Clinical Sciences & OperationsSanofi
- Intervention
- venglustat (GZ402671)(drug)
- Enrollment
- 12 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2026
Study locations (7)
- Yale University School of Medicine Site Number : 840002, New Haven, Connecticut, United States
- Baylor Institute of Metabolic Diseases Site Number : 840001, Dallas, Texas, United States
- Lysosomal and Rare Disorders Research and Treatment Center, Inc Site Number : 840003, Fairfax, Virginia, United States
- Investigational Site Number : 276001, Mainz, Germany
- Investigational Site Number : 392001, Minato-ku, Tokyo, Japan
- Investigational Site Number : 826003, Cambridge, Cambridgeshire, United Kingdom
- Investigational Site Number : 826002, Salford, Manchester, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02843035 on ClinicalTrials.govOther trials for Gaucher disease type 1
Additional recruiting or active studies for the same condition.